Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ALLO Allogene Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: ALLO
Price (delayed)
$0.9528
Market cap
$208.41M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.23
Enterprise value
$155.66M
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by
Highlights
The EPS has grown by 32% YoY and by 7% from the previous quarter
The net income has increased by 14% YoY and by 2% QoQ
ALLO's quick ratio is down by 24% year-on-year but it is up by 13% since the previous quarter
The gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
ALLO's revenue has dropped by 100% since the previous quarter and by 100% year-on-year
Key stats
What are the main financial stats of ALLO
Market
Valuations
Earnings
Shares outstanding
218.73M
Market cap
$208.41M
Enterprise value
$155.66M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.54
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$268.89M
Net income
-$252.32M
EBIT
-$251.55M
EBITDA
-$238.37M
Free cash flow
-$198.12M
Per share
Balance sheet
Liquidity
EPS
-$1.23
EPS diluted
-$1.23
Free cash flow per share
-$0.92
Book value per share
$1.77
Revenue per share
$0
TBVPS
$2.36
Total assets
$507.98M
Total liabilities
$122.59M
Debt
$0
Equity
$385.39M
Working capital
$261.55M
Debt to equity
0
Current ratio
9.71
Quick ratio
9.67
Net debt/EBITDA
0.22
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-44%
Return on equity
-56.5%
Return on invested capital
-54%
Return on capital employed
-52.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALLO stock price
How has the Allogene Therapeutics stock price performed over time
Intraday
-15.68%
1 week
-20.6%
1 month
-33.37%
1 year
-67.81%
YTD
-55.27%
QTD
-34.74%
Financial performance
How have Allogene Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$268.89M
Net income
-$252.32M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
ALLO's revenue has dropped by 100% since the previous quarter and by 100% year-on-year
The net income has increased by 14% YoY and by 2% QoQ
ALLO's operating income is up by 10% year-on-year
Price vs fundamentals
How does ALLO's price correlate with its fundamentals
Growth
What is Allogene Therapeutics's growth rate over time
Valuation
What is Allogene Therapeutics stock price valuation
P/E
N/A
P/B
0.54
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 32% YoY and by 7% from the previous quarter
ALLO's price to book (P/B) is 75% less than its 5-year quarterly average of 2.2 and 46% less than its last 4 quarters average of 1.0
Allogene Therapeutics's equity has decreased by 16% YoY and by 9% QoQ
ALLO's revenue has dropped by 100% since the previous quarter and by 100% year-on-year
Efficiency
How efficient is Allogene Therapeutics business performance
ALLO's return on invested capital is down by 8% year-on-year
The return on equity has declined by 5% year-on-year and by 2.2% since the previous quarter
The return on assets has declined by 2.1% year-on-year
Dividends
What is ALLO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALLO.
Financial health
How did Allogene Therapeutics financials performed over time
ALLO's quick ratio is down by 24% year-on-year but it is up by 13% since the previous quarter
ALLO's current ratio is down by 24% YoY but it is up by 14% from the previous quarter
Allogene Therapeutics's debt is 100% less than its equity
Allogene Therapeutics's equity has decreased by 16% YoY and by 9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.